14May2026
![[[TitleNews]]](/uploadfile/202605/5f66784bb225e07.jpg?size=300x0)
How Is Pembrolizumab Reshaping 2026 Oncology R&D Procurement?
read more
Discover 2026 sourcing trends for Pembrolizumab API (CAS 1374853-91-4). Shaanxi Sunrise offers high-purity materials for biosimilar & SC formulation R&D.
14May2026
![[[TitleNews]]](/uploadfile/202605/cf2e384ce7f62f3.jpg?size=300x0)
Paclitaxel (CAS 33069-62-4) in 2026: Efficacy and Sourcing
read more
Discover the 2026 market outlook for Paclitaxel (CAS 33069-62-4). Shaanxi Sunrise provides high-purity API sourcing, nanocarrier delivery insights, and clinical efficacy trends for global B2B procurement
08May2026
![[[TitleNews]]](/uploadfile/202605/e35c8cf10eeda3a.jpg?size=300x0)
Pembrolizumab API Supplier: CAS 1374853-91-4 Biopharma R&D
Secure high-purity Pembrolizumab API for biosimilar & PD-1 R&D. We guarantee ≥ SEC-HPLC monomer purity and ultra-low endotoxins (≤ 0.05 EU/mg).
read more